Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide Transnasal Nebulization for CRSwNP
NCT03687515Phase 3Completed
- Sponsor
- Beijing Tongren Hospital
- Start
- Jan 2015
- Primary completion
- Dec 2016
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, open-label trial of EPI-EE in chronic rhinosinusitis with nasal polyps (CRSwNP) (3 arms), sponsored by Beijing Tongren Hospital. Primary endpoint: Clinical responses including 4 major symptoms (nasal obstruction, rhinorrhea, loss of smell, and headache/facial pain) at 2 weeks. Started Jan 2015; status: completed.
02
Drugs
EPI-EE
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT03687515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03687515.